Nuvectis Pharma, Inc.
3 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer (NCT07315113) | Nuvectis Pharma, Inc. | 2025-12-18 |
| A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers (NCT05873686) | Nuvectis Pharma, Inc. | 2023-10-26 |
| A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer (NCT05226507) | Nuvectis Pharma, Inc. | 2021-12-31 |
Track Nuvectis Pharma, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.